Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Date:1/9/2008

ogical and other surgical and medical procedures. Omeros has three ongoing PharmacoSurgery clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-looking Statements

This press release contains "forward-looking statements." These statements include, but are not limited to, those regarding Omeros' proposed initial public offering and expectations regarding its clinical development activities and the clinical benefits of its product candidates. These forward-looking statements are based on the current intent and expectations of the management of Omeros. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Omeros' actual results and the timing and outcome of events may differ materially from those expressed in or implied by the forward-looking statements because of risks associated with Omeros' clinical development activities, regulatory oversight, intellectual property rights and other risks. Omeros undertakes no obligation to update any forward-looking or other statements in this press release, whether as a result of new information, future events or otherwise. SOURCE Omeros Corporation


'/>"/>
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 BioTech ... developments, patents and results of studies and trials.  Companies ... and Company (NYSE: LLY ), Gilead Sciences ... CELG ) and Arena Pharmaceuticals Inc. (NASDAQ: ... in developing prodrug therapeutics for the treatment of cancer, ...
(Date:9/19/2014)... Massachusetts , September 19, 2014 ... the 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... of science and medical research in the field of ... Merck KGaA, Darmstadt, Germany , today ... Innovation (GGI) for 2014. The awards were announced during ...
(Date:9/18/2014)... 18, 2014 About POCT ... outside a clinical laboratory. It helps in making ... treatments and medication. POCT is gaining popularity due ... diseases such as diabetes, heart disease, and obesity. ... are standardized to minimize errors during the diagnosis ...
(Date:9/18/2014)... Ireland , September 18, 2014 ... and Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has ... "Biocompatible Materials - Global Strategic Business ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes ... in US$ Million by the following ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... Sept. 27, 2011 Verenium Corporation (Nasdaq: ... commercializing high-performance enzymes, today announced that it retired its ... of $34.9 million in principal amount of unsecured 5.5% ... approximately $1.1 million in principal amount of its 9% ...
... nanowires may be coming to a little screen near you. ... the costs of displaying information on cell phones, e-readers and ... and improved solar cells, according to new research. Duke ... technique to organize copper atoms in water to form long, ...
... -- Two professors from the University of California, Riverside,s ... study a new approach that could allow the electronics ... in the next generation of computers. Alexander Balandin, ... materials science and engineering program, and Roger Lake, a ...
Cached Biology Technology:Verenium Announces Debt Repurchase 2Verenium Announces Debt Repurchase 3Copper film could lower touch screen, led and solar cell costs 2Bold approach could change electronics industry 2Bold approach could change electronics industry 3
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/17/2014)... to reproductive technologies, the justice and well-being of ... to identify key issues, articulate their values and ... most defensible ways forward. But what are the ... The Hastings Center and the Presidential Commission for ... to publish a series of essays to highlight ...
(Date:9/17/2014)... 17, 2014) A rare genetic disorder known as Jacobsen ... recent joint investigation by researchers at San Diego State ... addition to suggesting better treatment options for people with ... the genetic underpinnings of autism., Jacobsen syndrome affects approximately ... of Health. It occurs in a person when there ...
Breaking Biology News(10 mins):How stress tears us apart 2Why bioethics literacy matters 2Why bioethics literacy matters 3A link between Jacobsen syndrome and autism 2
... While testing a new drug designed to treat chronic ... could identify which patients would receive maximum benefit from ... the online edition of Blood , a weekly ... Chronic lymphocytic leukemia (CLL), a cancer of ...
... three types of cells derived from human embryonic stem cells ... but are much more developmentally immature than previously thought when ... tissue. The researchers, from the Eli and Edythe Broad ... found that the progeny of the human embryonic stem cells ...
... its kind, researchers have used tools of paleontology to gain ... have shown that during the evolution of these compounds nature ... to synthesise forms, giving pointers that will help in the ... record has allowed the study of the evolution of the ...
Cached Biology News:Cells derived from pluripotent stem cells are developmentally immature 2Cells derived from pluripotent stem cells are developmentally immature 3Nature reaches for the high-hanging fruit 2
...
... Rocker, with 12" x 14" table; 115V 512500-00 ... table; 220V. The VSR-50 Variable Speed Rocker ... lab. The VSR-50 provides a rhythmic side-to-side motion ... to vigourous movement. This makes it ideal for: ...
...
... Dyad instrument is the most advanced thermal ... world-class thermal performance, the Dyad also boasts ... as point-and-click navigation via touch pad or ... easily and economically expanded to a four-bay ...
Biology Products: